Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

This comprehensive analysis examines Merck's strategic position, financial performance, and future prospects in light of recent developments and analyst insights.

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

MERCK & CO INC (MRK) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 90% based on the firm’s underlying fundamentals and the stock’s valuation.

Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.

Technical indicators and charts suggest high risk for Merck, with the stock repeatedly breaking down. See why I rate MRK stock a strong sell.

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Merck? Access our full analysis report here, it’s free.

Although investors have assigned a higher P/S multiple for LLY stock owing to its pipeline potential, we believe this gap will narrow in favor of Merck.